ADA-SCID treatment: Enzyme replacement or transplant?

It is a time-dependent selection between metabolic control, definitive cellular correction, donor availability, infection status, and treatment-related risk.

For children with ADA-SCID, enzyme replacement therapy (ERT) can rapidly reduce toxic metabolite exposure and restore measurable immune function. It does not generally correct the underlying genetic defect. Hematopoietic cell transplantation (HCT) can provide definitive immune reconstitution, particularly when a matched sibling or matched family donor is available, but outcomes are strongly influenced by age and active infection at the time of treatment. Gene therapy represents a further definitive strategy in selected settings, although it should not be conflated with routine commercial availability in the United States.

The practical comparison of ADA-SCID enzyme replacement vs stem cell transplant therefore depends on the clinical state at diagnosis. ERT may be the immediate intervention. HCT or gene therapy may be the definitive intervention.

The role of enzyme replacement therapy as a metabolic bridge

ADA is required for the breakdown of deoxyadenosine. In ADA deficiency, toxic deoxyadenosine nucleotides, collectively measured as dAXP, accumulate. These metabolites are particularly damaging to lymphoid cells. The resulting phenotype is severe combined immunodeficiency, with impaired T-cell, B-cell, and natural killer cell function to variable degrees.

PEGylated adenosine deaminase replaces the missing enzymatic activity. In current practice, the relevant product is elapegademase-lvlr, marketed as Revcovi. The US Food and Drug Administration approved it on October 5, 2018. It replaced the older bovine-derived product pegademase bovine, known as Adagen, which was discontinued and replaced by Revcovi in 2019.

The biochemical objective is direct:

• restore ADA enzymatic activity;
• reduce circulating and intracellular toxic deoxyadenosine metabolites;
• limit further lymphocyte injury;
• create a more stable metabolic environment while definitive therapy is assessed.

The initial Revcovi regimen cited in the treatment data is 0.2 mg/kg administered intramuscularly twice weekly. The dose and subsequent management require clinical adjustment. Treatment is not defined only by the prescribed amount. Laboratory monitoring includes biochemical response, immune-cell parameters, and clinical evidence of infection or immune dysfunction.

ERT has a specific role in the treatment pathway. It is often used as a bridge to HCT or gene therapy, especially when a child presents with active infection, severe metabolic toxicity, or a delay in definitive treatment. The bridge is clinically meaningful because uncontrolled infection and metabolic injury can reduce the probability of successful cellular therapy.

ERT is not equivalent to correction of the ADA gene defect. The child remains dependent on replacement enzyme unless cellular therapy later establishes endogenous ADA production. Treatment therefore requires ongoing administration and monitoring. Loss of exposure can allow toxic metabolites to reaccumulate and immune function to deteriorate.

ERT controls the metabolic defect. It does not, by itself, remove the genetic defect.

The distinction matters when families compare peg-ADA therapy versus HSCT in children. The comparison is not between a low-risk permanent treatment and a high-risk temporary treatment. It is between a maintenance strategy with non-curative intent and a cellular strategy with curative potential but procedure-specific risks.

What ERT can and cannot establish

A favorable response to PEG-ADA should not be interpreted as proof that definitive therapy is unnecessary. Improvement in lymphocyte counts, infection burden, or metabolic biomarkers indicates pharmacologic activity. It does not demonstrate durable immune correction independent of treatment.

The response also does not eliminate the need for diagnostic precision. ADA-SCID must be distinguished from other inborn errors of immunity with overlapping clinical presentations. The molecular diagnosis identifies the pathogenic ADA variants. Enzyme activity and metabolite measurements support the functional interpretation. Immunophenotyping defines the cellular phenotype. These data are complementary rather than interchangeable.

A diagnostic and treatment dataset may include:

• ADA gene sequencing and confirmation of pathogenic variants;
• ADA enzyme activity testing;
• dAXP or related toxic metabolite assessment;
• complete blood count with differential;
• lymphocyte subset analysis;
• T-cell function testing;
• immunoglobulin measurements;
• microbiological evaluation for active infection.

The exact test configuration varies by laboratory and clinical setting. The underlying principle is stable: a treatment decision based only on a single biomarker has lower diagnostic resolution than one based on molecular, biochemical, cellular, and clinical data together.

Hematopoietic cell transplantation and donor influence

HCT replaces the defective hematopoietic system with donor-derived hematopoietic cells capable of producing immune cells with functional ADA activity. It is a potentially definitive treatment for ADA-SCID. The outcome depends on donor relationship, conditioning strategy, disease status, age, infection burden, and transplant-center expertise.

The strongest outcome data in the supplied long-term cohort concern matched sibling or matched family donors. In the Primary Immune Deficiency Treatment Consortium 35-year study of 131 patients with ADA-SCID, matched sibling or matched family donor HCT produced:

• 100% five-year overall survival;
• 90.5% five-year event-free survival.

These are not generic HCT results. They describe a defined donor category in a defined ADA-SCID cohort. They should not be extended to unrelated donors, mismatched donors, or all transplant protocols without qualification.

The same study reported different five-year overall survival values according to treatment sequence:

These categories should not be treated as randomized comparisons. Patients receiving each strategy may differ in age, infection status, donor availability, conditioning, disease severity, and referral timing. The values demonstrate the effect of treatment context. They do not establish that one pathway is universally superior for every child.

HCT also introduces complications that are not present in the same form with ongoing ERT. The transplant process may involve conditioning, graft failure, graft-versus-host disease, infections, and prolonged immune reconstitution. Risk is not eliminated by the presence of a donor. A matched donor improves the treatment profile but does not convert HCT into a zero-risk intervention.

HCT versus ERT: the core comparison

The central differences can be summarized as follows:

• Mechanism: ERT supplies missing ADA activity. HCT supplies donor-derived hematopoietic cells.
• Dependence on continued treatment: ERT requires ongoing injections. Successful HCT may establish durable endogenous immune-cell production.
• Genetic correction: ERT does not correct ADA pathogenic variants. HCT does not directly edit the patient's genome but can replace the defective hematopoietic compartment.
• Time to treatment: ERT can be initiated without waiting for donor-cell collection or transplant preparation.
• Definitive potential: ERT is generally non-curative. HCT has curative potential.
• Procedural risk: ERT is associated with chronic administration and monitoring. HCT carries transplant-specific risks, including graft failure and graft-versus-host disease.
• Dependence on disease status: ERT can be used to stabilize a child before definitive therapy. HCT outcomes are substantially affected by active infection and age.

The clinically relevant endpoint is not merely survival at treatment initiation. It includes event-free survival, durable immune reconstitution, freedom from lifelong enzyme replacement, infection control, and the burden of long-term monitoring.

Timing changes the HCT risk profile

Age at definitive cellular therapy is a major outcome variable. In the reported ADA-SCID cohort, HCT performed before 3.5 months of age produced a five-year overall survival of 91.6%. When HCT occurred at or after 3.5 months, five-year overall survival was 68%.

This is not a minor scheduling difference. It reflects the cumulative effect of infection exposure, inflammatory complications, metabolic injury, nutritional decline, and treatment complexity. ADA-SCID can be clinically heterogeneous, but a child who remains clinically stable is not equivalent to a child who reaches HCT after repeated infections or organ complications.

The timing data support early disease recognition. Newborn screening for SCID and rapid confirmatory testing can identify affected infants before severe infection develops. The diagnostic workflow must be fast enough to preserve treatment options. Delayed molecular confirmation has a direct clinical cost when the child becomes infected before definitive therapy.

The sequence is operationally important:

1. Detect abnormal immune screening or a compatible clinical phenotype.

2. Confirm the immunodeficiency with cellular, biochemical, and molecular testing.

3. Initiate infection prevention and supportive management.

4. Start ERT when metabolic stabilization is indicated.

5. Evaluate donor options and definitive cellular therapy without avoidable delay.

6. Proceed to HCT or gene therapy according to donor status, eligibility, infection control, and center-specific protocol.

This sequence is not a universal protocol. It is a diagnostic and treatment logic. The key metric is the interval between recognition of ADA-SCID and definitive immune reconstitution.

Active infection is a major prognostic discriminator

The presence of active infection at the time of definitive cellular therapy has a substantial association with outcome. In the reported study, five-year event-free survival was 33.1% in patients with active infection compared with 68.2% in those without active infection. Five-year overall survival was 64.7% with active infection versus 82.3% without it.

The numbers establish two separate points. First, infection-free status is clinically valuable. Second, ERT may function as more than a biochemical intervention when it allows time for infection control before HCT or gene therapy.

ERT does not replace antimicrobial management. It does not reverse established organ injury on demand. Its value is linked to the restoration of ADA activity and reduction of toxic metabolite burden while the broader clinical condition is stabilized.

The infection variable also changes how transplant results should be interpreted. A transplant performed in an infection-free infant and a transplant performed during uncontrolled infection belong to different risk strata. Reporting a single survival value for HCT without describing infection status removes clinically important information.

The decisive variable is often not ERT versus HCT in isolation. It is whether definitive therapy occurs before infection changes the risk profile.

For pediatric teams, this makes surveillance a central component of treatment. Clinical deterioration, persistent fever, pulmonary findings, mucosal disease, gastrointestinal symptoms, and microbiological results should be integrated with immune and biochemical markers. No single assay can substitute for clinical assessment, but assay trends can provide objective evidence of treatment response and deterioration.

Gene therapy changes the treatment landscape, but not the decision logic

Gene therapy is a definitive cellular strategy in which the patient's hematopoietic stem cells are modified ex vivo to restore ADA function before reinfusion. It differs from allogeneic HCT because it does not rely on a donor immune system. It also has its own eligibility requirements, manufacturing steps, conditioning requirements, and long-term follow-up obligations.

The supplied cohort reported five-year overall survival of 100% for ERT followed by gene therapy. This result is clinically important but should be read with methodological discipline. It is not a randomized head-to-head comparison with matched unrelated donor HCT. The available data do not establish a universal superiority ranking across all modern gene therapy and HCT platforms.

Strimvelis received European approval in 2016. That regulatory history demonstrates that ADA-SCID gene therapy is not a purely experimental concept. It does not mean that ex vivo gene therapy is widely available as an FDA-approved commercial treatment in the United States.

For a child with ADA-SCID, the practical treatment map remains dependent on access:

• an eligible matched sibling or matched family donor may support early HCT;
• absence of a suitable donor may shift consideration toward alternative donor HCT or gene therapy;
• active infection may require ERT and intensive stabilization before definitive treatment;
• geographic access and center expertise can determine whether a cellular option is technically available;
• molecular confirmation remains necessary for accurate disease classification and eligibility assessment.

The treatment decision cannot be reduced to the highest percentage in a retrospective table. The relevant question is whether the outcome data apply to the same donor category, age, infection status, conditioning strategy, and treatment sequence.

How to interpret the evidence in clinical practice

The comparison of ADA deficiency treatment options in children should be constructed around four variables: immediacy, reversibility, definitiveness, and risk stratification.

ERT scores highest for immediacy. It can be initiated as a metabolic intervention while donor searches, infection treatment, eligibility review, and cell-therapy planning proceed. It is also useful when immediate HCT would carry excessive risk because of active infection or clinical instability.

HCT scores highest when a suitable matched donor is available and treatment occurs early, particularly before severe infection develops. The reported 100% five-year overall survival with matched sibling or matched family donor HCT is a strong outcome signal. It remains a cohort-specific result, not a guarantee for every transplant candidate.

Gene therapy has definitive potential without an allogeneic donor. The reported five-year survival after ERT followed by gene therapy was 100% in the cited cohort. However, availability, regulatory status, protocol eligibility, manufacturing capacity, and long-term surveillance remain practical constraints.

A technically sound evaluation should separate three types of evidence:

• Diagnostic evidence: pathogenic ADA variants, enzyme activity, dAXP accumulation, and immune phenotype.
• Treatment-response evidence: biochemical detoxification, lymphocyte recovery, immune function, and infection control.
• Outcome evidence: overall survival, event-free survival, donor-specific results, age at treatment, and infection status.

These layers should not be collapsed. A child may have a clear molecular diagnosis but inadequate immune recovery on ERT. Another may show biochemical improvement but remain vulnerable to opportunistic infection. A third may have a favorable donor and early referral but require careful transplant preparation.

A compact decision matrix

The matrix is a route map, not a substitute for a transplant or immunology conference. The decisive variables are patient-specific and center-dependent.

Clinical utility of the assays

The diagnostic utility of ADA-SCID testing depends on analytical validity and clinical interpretation. Assay selection should reflect the question being asked.

Molecular sequencing identifies pathogenic variants. It provides the etiologic diagnosis and supports family testing. Variant interpretation requires attention to zygosity, inheritance, coverage, and the distinction between pathogenic variants and uncertain findings.

ADA enzyme activity testing addresses functional deficiency. It is not interchangeable with sequencing. A genetic result requires biological correlation, particularly when the variant classification is incomplete or when phenotype and genotype appear discordant.

Metabolite analysis evaluates the biochemical consequence of ADA deficiency and the response to ERT. The assay should be interpreted longitudinally where possible. A single result provides less information than a trend linked to treatment exposure and clinical status.

Immunophenotyping defines the immune-cell compartment. Lymphocyte counts alone are insufficient to characterize functional immune competence. T-cell, B-cell, and natural killer cell measurements provide a higher-resolution profile, but they still require integration with functional assays and infection history.

The operational parameters matter:

• Sensitivity: the ability to detect the relevant molecular or biochemical abnormality.
• Specificity: the ability to distinguish ADA-SCID from phenotypically similar immunodeficiencies.
• Turnaround time: the interval between specimen collection and a result that can change management.
• Throughput: relevant to newborn screening and high-volume confirmatory workflows.
• Orthogonal confirmation: use of independent assays when a result has major treatment implications.
• Preanalytic stability: specimen handling can affect cellular and biochemical measurements.

A high-throughput assay with poor clinical specificity is not an efficient diagnostic solution. A highly specific molecular assay with a clinically unusable turnaround time can still delay treatment. Diagnostic accuracy is therefore a system property, not merely a feature of one platform.

Final assessment

The evidence supports a staged treatment model for ADA-SCID.

ERT is an effective metabolic bridge. It detoxifies dAXP, supports immune function, and can reduce the clinical burden while definitive therapy is organized. It is generally not curative and requires ongoing injections unless the child transitions to cellular therapy.

HCT provides definitive curative potential. Outcomes are strongest with matched sibling or matched family donors and early treatment. In the reported cohort, five-year overall survival reached 100% in that donor group. Treatment after 3.5 months of age and treatment during active infection were associated with substantially worse outcomes.

Gene therapy provides another definitive route in selected patients. The available cohort data are favorable, including 100% five-year overall survival after ERT followed by gene therapy, but direct randomized comparisons with modern alternative HCT strategies are not established.

The clinical utility of ADA-SCID enzyme replacement versus stem cell transplant is therefore conditional. ERT is the immediate metabolic intervention. HCT is a donor-dependent definitive option. Gene therapy is a definitive cellular option when accessible and appropriate. Age, infection status, donor category, pathogenic variants, assay confirmation, and treatment-center capability determine the route.

The rigid conclusion is straightforward: ERT should not be mistaken for a permanent cure, and HCT should not be assessed without donor and infection stratification. The optimal pathway is the one that achieves definitive immune reconstitution before preventable infection and disease progression alter the outcome profile.